{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:50:05Z","timestamp":1778932205319,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.beem.2013.11.001","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T00:00:27Z","timestamp":1384473627000},"page":"453-461","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality"],"prefix":"10.1016","volume":"28","author":[{"given":"Marcin","family":"Barylski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Toth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dragana","family":"Nikolic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfredi","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Montalto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2013.11.001_bib1","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11883-003-0010-5","article-title":"Reverse cholesterol transport: high-density lipoprotein's magnificent mile","volume":"5","author":"Toth","year":"2003","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.beem.2013.11.001_bib2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.CIR.55.5.767","article-title":"HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study","volume":"55","author":"Castelli","year":"1977","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2013.11.001_bib3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0140-6736(77)92274-7","article-title":"The Troms\u00f8 heart-study. High-density lipoprotein and coronary heart disease: a prospective case-control study","volume":"1","author":"Miller","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2013.11.001_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.79.1.8","article-title":"High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies","volume":"79","author":"Gordon","year":"1989","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2013.11.001_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2013.11.001_bib6","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1161\/CIRCULATIONAHA.108.773747","article-title":"Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden","volume":"117","author":"Ballantyne","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2013.11.001_bib7","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacl.2007.02.004","article-title":"Should both HDL-C and LDL-C be targets for lipid therapy? A review of current evidence","volume":"1","author":"Brown","year":"2007","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.beem.2013.11.001_bib8","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2013.11.001_bib9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2013.11.001_bib10","unstructured":"http:\/\/www.ctsu.ox.ac.uk\/%7Ethrive\/."},{"key":"10.1016\/j.beem.2013.11.001_bib11","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2013.11.001_bib12","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/01.CIR.103.15.1949","article-title":"Cardiovascular status of carriers of the apolipoprotein A-I Milano mutant: the limone sul garda study","volume":"103","author":"Sirtori","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2013.11.001_bib13","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2013.11.001_bib14","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jacl.2010.08.018","article-title":"Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?","volume":"4","author":"Tardif","year":"2010","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.beem.2013.11.001_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.atherosclerosis.2011.10.006","article-title":"Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type)","volume":"220","author":"Ibanez","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.beem.2013.11.001_bib16","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"18","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.beem.2013.11.001_bib17","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1111\/j.1755-5922.2010.00221.x","article-title":"Reconstituted HDL in acute coronary syndromes","volume":"30","author":"Chenevard","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.beem.2013.11.001_bib18","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","article-title":"A\u00a0first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome","volume":"55","author":"Waksman","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2013.11.001_bib19","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1194\/jlr.M800622-JLR200","article-title":"Selective delipidation of plasma HDL enhances reverse cholesterol transport in\u00a0vivo","volume":"50","author":"Sacks","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib20","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0022-2275(20)31599-6","article-title":"Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide","volume":"42","author":"Datta","year":"2001","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib21","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/ATVBAHA.109.187518","article-title":"Structure and function of HDL mimetics","volume":"30","author":"Navab","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2013.11.001_bib22","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","article-title":"Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients","volume":"49","author":"Bloedon","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib23","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1194\/jlr.M011098","article-title":"Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function","volume":"52","author":"Watson","year":"2011","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib24","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.CIR.0000070589.61860.A9","article-title":"L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease","volume":"107","author":"Ou","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2013.11.001_bib25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/CRD.0b013e3181c4b508","article-title":"Apolipoprotein A-I mimetic peptides: a potential new therapy for the prevention of atherosclerosis","volume":"18","author":"Sherman","year":"2010","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.beem.2013.11.001_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/01.ATV.16.2.328","article-title":"Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly","volume":"16","author":"Palgunachari","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2013.11.001_bib27","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1074\/jbc.274.4.2021","article-title":"Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid","volume":"274","author":"Gillotte","year":"1999","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2013.11.001_bib28","doi-asserted-by":"crossref","first-page":"24044","DOI":"10.1074\/jbc.M400561200","article-title":"Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1","volume":"279","author":"Natarajan","year":"2004","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2013.11.001_bib29","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1021\/bi602407r","article-title":"The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins","volume":"46","author":"Vedhachalam","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.beem.2013.11.001_bib30","doi-asserted-by":"crossref","first-page":"32273","DOI":"10.1074\/jbc.M804461200","article-title":"Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides","volume":"283","author":"Sethi","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2013.11.001_bib31","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1194\/jlr.M003665","article-title":"A\u00a0new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice","volume":"51","author":"Bielicki","year":"2010","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib32","first-page":"1042","article-title":"Loss-offunction variants in endothelial lipase are a cause of elevated HDL cholesterol in humans","volume":"119","author":"Edmondson","year":"2009","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2013.11.001_bib33","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.1371\/journal.pmed.0030022","article-title":"Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis","volume":"3","author":"Badellino","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.beem.2013.11.001_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1194\/jlr.M700399-JLR200","article-title":"Protective effect of an endothelial lipase gene variant on coronary artery disease in a Chinese population","volume":"49","author":"Tang","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1056\/NEJMoa0907687","article-title":"Genetic variant of the scavenger receptor BI in humans","volume":"364","author":"Vergeer","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beem.2013.11.001_bib36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1172\/JCI16306","article-title":"Endothelial lipase is a major determinant of HDL level","volume":"111","author":"Ishida","year":"2003","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2013.11.001_bib37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrcardio.2010.200","article-title":"Novel HDL-directed pharmacotherapeutic strategies","volume":"8","author":"deGoma","year":"2011","journal-title":"Nature Rev Cardiol"},{"key":"10.1016\/j.beem.2013.11.001_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nature09270","article-title":"Biological, clinical and population relevance of 95 loci for blood lipids","volume":"466","author":"Teslovich","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.beem.2013.11.001_bib39","unstructured":"http:\/\/circ.ahajournals.org\/cgi\/content\/meeting_abstract\/120\/18_MeetingAbstracts\/S1175-b."},{"key":"10.1016\/j.beem.2013.11.001_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11883-011-0171-6","article-title":"Lecithin cholesterol acyltransferase: an anti- or proatherogenic factor?","volume":"13","author":"Rousset","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.beem.2013.11.001_bib41","first-page":"C181","article-title":"Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy","volume":"301","author":"Asada","year":"2011","journal-title":"Am J Phys"},{"key":"10.1016\/j.beem.2013.11.001_bib42","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1172\/JCI30163","article-title":"Molecular regulation of HDL metabolism and function: implications for novel therapies","volume":"116","author":"Rader","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2013.11.001_bib43","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1016\/j.jacc.2010.02.035","article-title":"RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in\u00a0vitro and in\u00a0vivo","volume":"55","author":"Bailey","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2013.11.001_bib44","series-title":"Proceedings of the American College of Cardiology Scientific Sessions, Orlando, Fla, USA","article-title":"RVX-208 a small molecule that induces apolipoprotein A-I production progresses to phase Ib\/IIa clinical trials","author":"Gordon","year":"2009"},{"key":"10.1016\/j.beem.2013.11.001_bib45","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","article-title":"Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease: a randomized controlled trial","volume":"57","author":"Nicholls","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.beem.2013.11.001_bib46","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10557-012-6373-5","article-title":"ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies","volume":"26","author":"Nicholls","year":"2012","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.beem.2013.11.001_bib47","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrcardio.2011.37","article-title":"Atherosclerosis: targeting endogenous apoA-I \u2013 a new approach for raising HDL","volume":"8","author":"Shah","year":"2011","journal-title":"Nature Rev Cardiol"},{"key":"10.1016\/j.beem.2013.11.001_bib48","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2010.07.002","article-title":"Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis","volume":"12","author":"Lo Sasso","year":"2010","journal-title":"Cell Metab"},{"key":"10.1016\/j.beem.2013.11.001_bib49","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.plipres.2010.03.002","article-title":"The liver X receptor: control of cellular lipid homeostasis and beyond: implications for drug design","volume":"49","author":"Oosterveer","year":"2010","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib50","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/ATVBAHA.109.195693","article-title":"Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in\u00a0vivo","volume":"30","author":"Yasuda","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.beem.2013.11.001_bib51","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1161\/01.RES.0000184678.43488.9f","article-title":"Liver X receptor activation controls intracellular cholesterol trafficking and esterification in human macrophages","volume":"97","author":"Rigamonti","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.beem.2013.11.001_bib52","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1194\/jlr.M900037-JLR200","article-title":"LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse","volume":"50","author":"Quinet","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib53","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0091270009335768","article-title":"Safety, pharmacokinetics, and pharmacodynamics of single doses of lxr-623, a novel liver X-receptor agonist, in healthy participants","volume":"49","author":"Katz","year":"2009","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.beem.2013.11.001_bib54","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1172\/JCI31909","article-title":"Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE","volume":"117","author":"Bradley","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2013.11.001_bib55","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1476-5381.2011.01202.x","article-title":"Anovel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR-\/- mice","volume":"162","author":"Peng","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.beem.2013.11.001_bib56","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1582-4934.2009.00997.x","article-title":"FXR an emerging therapeutic target for the treatment of atherosclerosis","volume":"14","author":"Mencarelli","year":"2010","journal-title":"J\u00a0Cell Mol Med"},{"key":"10.1016\/j.beem.2013.11.001_bib57","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1124\/jpet.112.196519","article-title":"Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (\u2212\/\u2212) mice","volume":"343","author":"Hambruch","year":"2012","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.beem.2013.11.001_bib58","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.plipres.2009.11.001","article-title":"Bile acid-activated receptors in the treatment of dyslipidemia and related disorders","volume":"49","author":"Fiorucci","year":"2010","journal-title":"Prog Lipid Res"},{"key":"10.1016\/j.beem.2013.11.001_bib59","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse","volume":"91","author":"Plump","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2013.11.001_bib60","doi-asserted-by":"crossref","first-page":"23610","DOI":"10.1016\/S0021-9258(17)31559-4","article-title":"Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia","volume":"269","author":"Maeda","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beem.2013.11.001_bib61","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121","author":"Rayner","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beem.2013.11.001_bib62","doi-asserted-by":"crossref","first-page":"12228","DOI":"10.1073\/pnas.1005191107","article-title":"miR-33 links SREBP-2 induction to repression of sterol transporters","volume":"107","author":"Marquart","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.beem.2013.11.001_bib63","doi-asserted-by":"crossref","first-page":"17321","DOI":"10.1073\/pnas.1008499107","article-title":"MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in\u00a0vivo","volume":"107","author":"Horie","year":"2010","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X13001619?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X13001619?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:49:31Z","timestamp":1761497371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X13001619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S1521690X13001619"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2013.11.001","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging therapies for raising high-density lipoprotein cholesterol (HDL-C) and augmenting HDL particle functionality","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2013.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}